AAPG
Ascentage Pharma Group Internat
Price Chart
Latest Quote
$23.17
Current Price| Previous Close | $24.18 |
| Open | $23.50 |
| Day High | $23.50 |
| Day Low | $23.17 |
| Volume | 1,413 |
Stock Information
Note: Financial values converted from CNY to USD
| Shares Outstanding | 92.96M |
| Total Debt | $247.08M |
| Cash Equivalents | $239.20M |
| Revenue | $56.24M |
| Net Income | $-166.89M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.17B |
| EPS (TTM) | $-2.09 |
| Exchange | NGM |
đ Custom Metrics & Score
Score: 9/42| Debt to Equity | 6.32 |
| Debt to Earnings | 1.75 |
| Current Ratio | 1.26 |
| Quick Ratio | 1.14 |
| Avg Revenue Growth | 853.40% |
| Profit Margin | -41.34% |
| Return on Equity | -153.46% |
| Avg FCF Growth | -21.74% |
| FCF Yield | -6.26% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $23.17 | 1,413 |
| 2026-01-30 | $24.18 | 9,600 |
| 2026-01-29 | $25.00 | 2,300 |
| 2026-01-28 | $25.30 | 2,100 |
| 2026-01-27 | $25.59 | 0 |
| 2026-01-26 | $25.59 | 5,900 |
| 2026-01-23 | $26.48 | 1,900 |
| 2026-01-22 | $26.20 | 900 |
| 2026-01-21 | $26.39 | 8,700 |
| 2026-01-20 | $26.01 | 4,300 |
| 2026-01-16 | $27.05 | 4,600 |
| 2026-01-15 | $27.30 | 2,800 |
| 2026-01-14 | $28.32 | 2,000 |
| 2026-01-13 | $27.77 | 1,900 |
| 2026-01-12 | $28.38 | 1,500 |
| 2026-01-09 | $28.78 | 1,400 |
| 2026-01-08 | $27.89 | 3,200 |
| 2026-01-07 | $28.22 | 14,400 |
| 2026-01-06 | $26.01 | 4,800 |
| 2026-01-05 | $26.95 | 3,300 |
About Ascentage Pharma Group Internat
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
đ° Latest News
Is Ascentage Pharma Group (SEHK:6855) Price Swings Creating A Valuation Opportunity Now
Simply Wall St. âĸ 2026-01-15T17:08:32Z
Ascentage: Partnership With Takeda Going Well
Bloomberg âĸ 2026-01-14T05:10:00Z
Ascentage Pharma B-Cell Cancer Candidate Receives FDA IND Clearance
Exec Edge âĸ 2026-01-07T22:09:17Z
Is Ascentage Pharma Group International Still Attractive After Its Big Multi Year Price Surge?
Simply Wall St. âĸ 2025-12-14T09:14:47Z
An Arch-backed biotech raises $53M to fight neurodegeneration
BioPharma Dive âĸ 2025-12-04T12:27:37Z
Global Growth Companies With High Insider Ownership And 36% Earnings Growth
Simply Wall St. âĸ 2025-11-24T09:35:39Z
Asian Growth Companies With High Insider Ownership To Watch
Simply Wall St. âĸ 2025-11-24T04:35:32Z
Asian Growth Companies With Up To 31% Insider Ownership
Simply Wall St. âĸ 2025-11-23T22:37:50Z
3 Global Growth Companies With High Insider Ownership Growing Earnings At 63%
Simply Wall St. âĸ 2025-11-21T09:35:51Z
Asian Growth Stocks Backed By Insider Confidence
Simply Wall St. âĸ 2025-11-21T04:35:39Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $29,085,000 | $30,543,000 | $21,998,000 | $3,328,000 |
| Cost Of Revenue | $29,085,000 | $30,543,000 | $21,998,000 | $3,328,000 |
| Total Revenue | $980,650,000 | $221,984,000 | $209,711,000 | $27,910,000 |
| Operating Revenue | $980,650,000 | $221,984,000 | $209,711,000 | $27,910,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $64,455,000 | $96,057,000 | $52,785,000 | $16,731,000 |
| Total Expenses | $1,350,380,000 | $1,094,620,000 | $1,059,521,000 | $897,745,000 |
| Other Income Expense | $1,090,000 | $3,422,000 | $5,696,000 | $47,211,000 |
| Other Non Operating Income Expenses | $-4,441,000 | $-1,402,000 | $-3,060,000 | $-23,377,000 |
| Net Non Operating Interest Income Expense | $-26,615,000 | $-63,648,000 | $-43,058,000 | $-9,625,000 |
| Interest Expense Non Operating | $64,455,000 | $96,057,000 | $52,785,000 | $16,731,000 |
| Operating Expense | $1,321,295,000 | $1,064,077,000 | $1,037,523,000 | $894,417,000 |
| Other Operating Expenses | $-9,073,000 | $-19,358,000 | $-33,597,000 | $-63,335,000 |
| Selling And Marketing Expense | $195,998,000 | $195,387,000 | $157,421,000 | $47,748,000 |
| General And Administrative Expense | $187,125,000 | $181,076,000 | $170,595,000 | $143,513,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-405,433,000 | $-925,637,000 | $-882,924,000 | $-782,424,000 |
| Net Interest Income | $-26,615,000 | $-63,648,000 | $-43,058,000 | $-9,625,000 |
| Interest Income | $37,840,000 | $32,409,000 | $9,727,000 | $7,106,000 |
| Normalized Income | $-409,792,000 | $-929,356,273 | $-891,912,830 | $-848,776,720 |
| Net Income From Continuing And Discontinued Operation | $-405,433,000 | $-925,637,000 | $-882,924,000 | $-782,424,000 |
| Net Income Common Stockholders | $-405,433,000 | $-925,637,000 | $-882,924,000 | $-782,424,000 |
| Net Income | $-405,433,000 | $-925,637,000 | $-882,924,000 | $-782,424,000 |
| Net Income Including Noncontrolling Interests | $-405,680,000 | $-925,712,000 | $-882,924,000 | $-782,424,000 |
| Net Income Continuous Operations | $-405,680,000 | $-925,712,000 | $-882,924,000 | $-782,424,000 |
| Pretax Income | $-395,255,000 | $-932,862,000 | $-887,172,000 | $-832,249,000 |
| Special Income Charges | $-50,000 | $4,000 | $2,068,000 | $-34,000 |
| Earnings From Equity Interest | $-281,000 | $1,076,000 | $-278,000 | $0 |
| Interest Income Non Operating | $37,840,000 | $32,409,000 | $9,727,000 | $7,106,000 |
| Operating Income | $-369,730,000 | $-872,636,000 | $-849,810,000 | $-869,835,000 |
| Gross Profit | $951,565,000 | $191,441,000 | $187,713,000 | $24,582,000 |
| Depreciation Amortization Depletion Income Statement | - | - | - | $13,365,000 |
| Depreciation And Amortization In Income Statement | - | - | - | $13,365,000 |
| Depreciation Income Statement | - | - | - | $13,365,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-5.36 | $-13.12 | $-13.40 | $-12.28 |
| Basic EPS | $-5.36 | $-13.12 | $-13.40 | $-12.28 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $1,453,000 | $28,727 | $45,170 | $4,235,280 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-243,443,000 | $-747,358,000 | $-780,506,000 | $-857,780,000 |
| Total Unusual Items | $5,812,000 | $3,748,000 | $9,034,000 | $70,588,000 |
| Total Unusual Items Excluding Goodwill | $5,812,000 | $3,748,000 | $9,034,000 | $70,588,000 |
| Reconciled Depreciation | $93,169,000 | $93,195,000 | $62,915,000 | $28,326,000 |
| EBITDA (Bullshit earnings) | $-237,631,000 | $-743,610,000 | $-771,472,000 | $-787,192,000 |
| EBIT | $-330,800,000 | $-836,805,000 | $-834,387,000 | $-815,518,000 |
| Diluted Average Shares | $75,515,526 | $70,574,817 | $65,922,207 | $63,653,830 |
| Basic Average Shares | $75,515,526 | $70,574,817 | $65,922,207 | $63,653,830 |
| Diluted NI Availto Com Stockholders | $-405,433,000 | $-925,637,000 | $-882,924,000 | $-782,424,000 |
| Minority Interests | $247,000 | $75,000 | $0 | - |
| Tax Provision | $10,425,000 | $-7,150,000 | $-4,248,000 | $-49,825,000 |
| Gain On Sale Of Ppe | $-50,000 | $4,000 | $2,068,000 | $-34,000 |
| Gain On Sale Of Security | $5,862,000 | $3,744,000 | $6,966,000 | $70,622,000 |
| Research And Development | $947,245,000 | $706,972,000 | $743,104,000 | $766,491,000 |
| Selling General And Administration | $383,123,000 | $376,463,000 | $328,016,000 | $191,261,000 |
| Other Gand A | $187,125,000 | $181,076,000 | $170,595,000 | $143,513,000 |
| Otherunder Preferred Stock Dividend | - | $0 | $0 | $0 |
| Other Special Charges | - | $-4,000 | $-2,068,000 | $34,000 |
| Salaries And Wages | - | - | - | $80,007,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $163,502,000 | $-49,723,000 | $299,660,000 | $1,149,632,000 |
| Total Assets | $2,617,810,000 | $2,500,393,000 | $2,830,261,000 | $2,940,060,000 |
| Total Non Current Assets | $1,143,648,000 | $1,156,215,000 | $1,193,773,000 | $1,054,780,000 |
| Non Current Prepaid Assets | $2,439,000 | $3,000,000 | $6,500,000 | $0 |
| Non Current Deferred Assets | $74,765,000 | $59,842,000 | $54,294,000 | $51,648,000 |
| Non Current Deferred Taxes Assets | $44,236,000 | $59,842,000 | $54,294,000 | $51,648,000 |
| Non Current Accounts Receivable | $26,034,000 | $7,052,000 | - | $35,880,000 |
| Investmentin Financial Assets | $1,141,000 | $1,951,000 | $2,609,000 | $11,645,000 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $1,141,000 | $1,951,000 | $2,609,000 | $11,645,000 |
| Goodwill And Other Intangible Assets | $100,692,000 | $110,140,000 | $108,998,000 | $85,105,000 |
| Other Intangible Assets | $75,998,000 | $85,446,000 | $84,304,000 | $60,411,000 |
| Current Assets | $1,474,162,000 | $1,344,178,000 | $1,636,488,000 | $1,885,280,000 |
| Restricted Cash | $24,633,000 | $24,537,000 | $16,601,000 | $36,935,000 |
| Prepaid Assets | $107,280,000 | $70,638,000 | $73,311,000 | $61,078,000 |
| Inventory | $6,597,000 | $16,167,000 | $9,448,000 | $3,930,000 |
| Receivables | $99,074,000 | $163,540,000 | $61,489,000 | $76,451,000 |
| Other Receivables | $6,137,000 | $6,637,000 | $649,000 | $159,000 |
| Taxes Receivable | $9,794,000 | $11,010,000 | $6,484,000 | $22,324,000 |
| Accounts Receivable | $83,143,000 | $145,893,000 | $54,356,000 | $53,968,000 |
| Cash Cash Equivalents And Short Term Investments | $1,236,578,000 | $1,069,296,000 | $1,475,639,000 | $1,706,886,000 |
| Cash And Cash Equivalents | $1,236,578,000 | $1,069,296,000 | $1,475,639,000 | $1,706,886,000 |
| Cash Equivalents | $343,478,000 | $31,248,000 | $130,000,000 | $0 |
| Cash Financial | $893,100,000 | $1,038,048,000 | $1,345,639,000 | $1,706,886,000 |
| Other Non Current Assets | - | - | $7,803,000 | $45,814,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $401,687,000 | $703,618,000 | $299,866,000 | - |
| Total Debt | $1,668,497,000 | $1,795,595,000 | $1,792,727,000 | $1,084,290,000 |
| Long Term Debt And Capital Lease Obligation | $889,435,000 | $1,179,191,000 | $1,274,344,000 | $1,034,839,000 |
| Long Term Debt | $868,642,000 | $1,166,267,000 | $1,265,200,000 | $1,026,592,000 |
| Current Debt And Capital Lease Obligation | $779,062,000 | $616,404,000 | $518,383,000 | $49,451,000 |
| Current Debt | $769,623,000 | $606,647,000 | $510,305,000 | $39,800,000 |
| Other Current Borrowings | $769,623,000 | $606,647,000 | $510,305,000 | $39,800,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $2,343,648,000 | $2,429,761,000 | $2,421,603,000 | $1,705,323,000 |
| Total Non Current Liabilities Net Minority Interest | $1,177,037,000 | $1,495,588,000 | $1,540,451,000 | $1,344,214,000 |
| Other Non Current Liabilities | $6,274,000 | - | - | - |
| Tradeand Other Payables Non Current | $0 | $18,299,000 | $35,331,000 | $52,343,000 |
| Non Current Deferred Liabilities | $281,328,000 | $298,098,000 | $230,776,000 | $257,032,000 |
| Non Current Deferred Taxes Liabilities | $5,368,000 | $10,549,000 | $12,151,000 | $13,753,000 |
| Current Liabilities | $1,166,611,000 | $934,173,000 | $881,152,000 | $361,109,000 |
| Current Deferred Liabilities | $54,085,000 | $38,410,000 | $24,354,000 | $24,358,000 |
| Payables And Accrued Expenses | $333,464,000 | $279,359,000 | $335,593,000 | $265,044,000 |
| Payables | $251,608,000 | $231,277,000 | $299,708,000 | $252,563,000 |
| Other Payable | $150,015,000 | $150,443,000 | $196,970,000 | $178,423,000 |
| Total Tax Payable | $9,627,000 | $8,389,000 | $7,179,000 | $3,279,000 |
| Accounts Payable | $91,966,000 | $72,445,000 | $95,559,000 | $70,861,000 |
| Interest Payable | - | $1,046,000 | $383,000 | $369,000 |
| Other Current Liabilities | - | - | $2,822,000 | $22,256,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $264,194,000 | $60,417,000 | $408,658,000 | $1,234,737,000 |
| Total Equity Gross Minority Interest | $274,162,000 | $70,632,000 | $408,658,000 | $1,234,737,000 |
| Stockholders Equity | $264,194,000 | $60,417,000 | $408,658,000 | $1,234,737,000 |
| Gains Losses Not Affecting Retained Earnings | $-510,586,000 | $-504,461,000 | $-518,514,000 | $-550,949,000 |
| Other Equity Adjustments | $-384,515,000 | $-371,441,000 | $-359,235,000 | $-330,173,000 |
| Retained Earnings | $-5,770,555,000 | $-5,365,122,000 | $-4,439,485,000 | $-3,556,561,000 |
| Long Term Equity Investment | $32,717,000 | $16,998,000 | $15,922,000 | $16,200,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $315,224,993 | $290,196,560 | $265,185,950 | $262,880,613 |
| Share Issued | $315,224,993 | $290,196,560 | $265,185,950 | $262,880,613 |
| Tangible Book Value | $163,502,000 | $-49,723,000 | $299,660,000 | $1,149,632,000 |
| Invested Capital | $1,902,459,000 | $1,833,331,000 | $2,184,163,000 | $2,301,129,000 |
| Working Capital | $307,551,000 | $410,005,000 | $755,336,000 | $1,524,171,000 |
| Capital Lease Obligations | $30,232,000 | $22,681,000 | $17,222,000 | $17,898,000 |
| Total Capitalization | $1,132,836,000 | $1,226,684,000 | $1,673,858,000 | $2,261,329,000 |
| Minority Interest | $9,968,000 | $10,215,000 | $0 | - |
| Foreign Currency Translation Adjustments | $-126,071,000 | $-133,020,000 | $-159,279,000 | $-220,776,000 |
| Treasury Stock | $8,000 | $21,351,000 | $26,552,000 | $3,000 |
| Additional Paid In Capital | $6,545,129,000 | $5,951,154,000 | $5,393,029,000 | $5,342,072,000 |
| Capital Stock | $214,000 | $197,000 | $180,000 | $178,000 |
| Common Stock | $214,000 | $197,000 | $180,000 | $178,000 |
| Non Current Deferred Revenue | $275,960,000 | $287,549,000 | $218,625,000 | $243,279,000 |
| Long Term Capital Lease Obligation | $20,793,000 | $12,924,000 | $9,144,000 | $8,247,000 |
| Current Deferred Revenue | $54,085,000 | $38,410,000 | $24,354,000 | $24,358,000 |
| Current Capital Lease Obligation | $9,439,000 | $9,757,000 | $8,078,000 | $9,651,000 |
| Current Accrued Expenses | $81,856,000 | $48,082,000 | $35,885,000 | $12,481,000 |
| Investments And Advances | $33,858,000 | $18,949,000 | $18,531,000 | $27,845,000 |
| Investmentsin Joint Venturesat Cost | $32,717,000 | $16,998,000 | $15,922,000 | $16,200,000 |
| Goodwill | $24,694,000 | $24,694,000 | $24,694,000 | $24,694,000 |
| Net PPE | $905,860,000 | $957,232,000 | $650,025,000 | $854,302,000 |
| Accumulated Depreciation | $-221,443,000 | $-150,831,000 | $-70,575,000 | $-41,887,000 |
| Gross PPE | $1,127,303,000 | $1,108,063,000 | $720,600,000 | $896,189,000 |
| Leases | $44,239,000 | $29,218,000 | $7,741,000 | $8,135,000 |
| Construction In Progress | $7,594,000 | $12,815,000 | $40,794,000 | $372,793,000 |
| Machinery Furniture Equipment | $183,343,000 | $179,865,000 | $155,212,000 | $60,977,000 |
| Buildings And Improvements | $865,659,000 | $858,567,000 | $488,125,000 | $424,426,000 |
| Land And Improvements | $26,468,000 | $27,598,000 | $28,728,000 | $29,858,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $3,861,000 | $11,078,000 | $4,410,000 | $1,782,000 |
| Work In Process | $2,736,000 | $5,089,000 | $5,038,000 | $2,148,000 |
| Investment Properties | - | $0 | $355,425,000 | $0 |
| Other Properties | - | - | $648,722,000 | $9,934,000 |
| Line Of Credit | - | - | - | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-135,646,000 | $-782,921,000 | $-890,878,000 | $-1,041,308,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-111,357,000 | $-726,077,000 | $-653,915,000 | $-604,679,000 |
| Cash Flow From Continuing Operating Activities | $-111,357,000 | $-726,077,000 | $-653,915,000 | $-604,679,000 |
| Operating Gains Losses | $-6,363,000 | $-5,523,000 | $-18,521,000 | $-95,040,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-24,289,000 | $-56,844,000 | $-236,963,000 | $-436,629,000 |
| Investing Cash Flow | $-362,035,000 | $21,922,000 | $-384,612,000 | $-466,522,000 |
| Cash Flow From Continuing Investing Activities | $-362,035,000 | $21,922,000 | $-384,612,000 | $-466,522,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $0 | $-5,923,000 | $-26,776,000 | $-25,874,000 |
| Issuance Of Capital Stock | $533,940,000 | $470,081,000 | $0 | $1,196,771,000 |
| Financing Cash Flow | $314,767,000 | $368,751,000 | $619,268,000 | $1,781,387,000 |
| Cash Flow From Continuing Financing Activities | $314,767,000 | $368,751,000 | $619,268,000 | $1,781,387,000 |
| Net Other Financing Charges | $-13,283,000 | $10,290,000 | - | $-16,071,000 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $533,940,000 | $464,158,000 | $-26,776,000 | $1,170,897,000 |
| Common Stock Issuance | $533,940,000 | $470,081,000 | $0 | $1,196,771,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-681,263,000 | $-966,857,000 | $-67,743,000 | $-60,242,000 |
| Issuance Of Debt | $535,923,000 | $953,500,000 | $763,617,000 | $599,737,000 |
| End Cash Position | $893,100,000 | $1,038,048,000 | $1,345,639,000 | $1,706,886,000 |
| Beginning Cash Position | $1,038,048,000 | $1,345,639,000 | $1,706,886,000 | $1,019,979,000 |
| Effect Of Exchange Rate Changes | $13,677,000 | $27,813,000 | $58,012,000 | $-23,279,000 |
| Changes In Cash | $-158,625,000 | $-335,404,000 | $-419,259,000 | $710,186,000 |
| Interest Paid Cff | $-60,556,000 | $-92,348,000 | $-49,849,000 | $-16,808,000 |
| Proceeds From Stock Option Exercised | $6,000 | $8,000 | $19,000 | $103,874,000 |
| Common Stock Payments | $0 | $-5,923,000 | $-26,776,000 | $-25,874,000 |
| Net Issuance Payments Of Debt | $-145,340,000 | $-13,357,000 | $695,874,000 | $539,495,000 |
| Net Long Term Debt Issuance | $-145,340,000 | $-13,357,000 | $695,874,000 | $539,495,000 |
| Long Term Debt Payments | $-681,263,000 | $-966,857,000 | $-67,743,000 | $-60,242,000 |
| Long Term Debt Issuance | $535,923,000 | $953,500,000 | $763,617,000 | $599,737,000 |
| Net Investment Purchase And Sale | $-312,230,000 | $98,752,000 | $-130,000,000 | $5,972,000 |
| Net Business Purchase And Sale | $-25,516,000 | $-20,000,000 | $-20,000,000 | $-36,200,000 |
| Purchase Of Business | $-25,516,000 | $-20,000,000 | $-20,000,000 | $-36,200,000 |
| Net Intangibles Purchase And Sale | $0 | $-10,736,000 | $-33,675,000 | $-1,214,000 |
| Purchase Of Intangibles | $0 | $-10,736,000 | $-33,675,000 | $-1,214,000 |
| Net PPE Purchase And Sale | $-24,289,000 | $-46,094,000 | $-200,937,000 | $-435,080,000 |
| Sale Of PPE | $0 | $14,000 | $2,351,000 | $335,000 |
| Purchase Of PPE | $-24,289,000 | $-46,108,000 | $-203,288,000 | $-435,415,000 |
| Change In Working Capital | $110,966,000 | $-9,146,000 | $104,413,000 | $189,653,000 |
| Change In Other Working Capital | $3,990,000 | $75,044,000 | $-4,324,000 | $194,873,000 |
| Change In Other Current Assets | $-48,950,000 | $-3,552,000 | $29,380,000 | $15,044,000 |
| Change In Payables And Accrued Expense | $98,027,000 | $25,459,000 | $82,146,000 | $65,372,000 |
| Change In Payable | $98,027,000 | $25,459,000 | $82,146,000 | $65,372,000 |
| Change In Account Payable | $19,521,000 | $-23,114,000 | $24,698,000 | $47,500,000 |
| Change In Prepaid Assets | $-14,421,000 | $-7,841,000 | $3,117,000 | $-17,677,000 |
| Change In Inventory | $9,570,000 | $-6,719,000 | $-5,518,000 | $-3,930,000 |
| Change In Receivables | $62,750,000 | $-91,537,000 | $-388,000 | $-53,968,000 |
| Changes In Account Receivables | $62,750,000 | $-91,537,000 | $-388,000 | $-53,968,000 |
| Other Non Cash Items | $64,370,000 | $96,057,000 | $52,580,000 | $34,647,000 |
| Stock Based Compensation | $20,924,000 | $31,503,000 | $22,105,000 | $46,971,000 |
| Unrealized Gain Loss On Investment Securities | $832,000 | $699,000 | $9,765,000 | $26,859,000 |
| Depreciation Amortization Depletion | $93,169,000 | $93,195,000 | $62,915,000 | $28,326,000 |
| Depreciation And Amortization | $93,169,000 | $93,195,000 | $62,915,000 | $28,326,000 |
| Amortization Cash Flow | $10,851,000 | $10,399,000 | $9,782,000 | $7,208,000 |
| Amortization Of Intangibles | $10,851,000 | $10,399,000 | $9,782,000 | $7,208,000 |
| Depreciation | $82,318,000 | $82,796,000 | $53,133,000 | $21,118,000 |
| Earnings Losses From Equity Investments | $281,000 | $-1,076,000 | $278,000 | $0 |
| Net Foreign Currency Exchange Gain Loss | $-6,694,000 | $-1,621,000 | $2,703,000 | $-7,505,000 |
| Gain Loss On Sale Of PPE | $50,000 | $-4,000 | $-2,068,000 | $34,000 |
| Net Income From Continuing Operations | $-395,255,000 | $-932,862,000 | $-887,172,000 | $-832,249,000 |
| Gain Loss On Investment Securities | - | $-2,822,000 | $-19,434,000 | $-87,569,000 |
| Sale Of Investment | - | - | $0 | $1,789,788,000 |
| Purchase Of Investment | - | - | $-130,000,000 | $-1,783,816,000 |
| Taxes Refund Paid | - | - | $0 | $-3,846,000 |
| Change In Other Current Liabilities | - | - | $0 | $-10,061,000 |